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Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted
treatments such as lenalidomide and bortezomib, most MM patients’ relapse is emphasizing the need for eﬀective and well-
tolerated therapies for this deadly disease. The use of oncolytic viruses has garnered signiﬁcant interest as cancer therapeutics
in recent years, and are currently under intense clinical investigation. Both naturally occurring and engineered DNA and RNA
viruses have been investigated preclinically as treatment modalities for several solid and hematological malignancies. Presently,
only a genetically modiﬁed measles virus is in human clinical trials for MM. The informationobtained from this and other future
clinicaltrials willguide clinicalapplicationofoncolyticviruses asanticancer agentsforMM.This paper provides atimely overview
of the history of oncolytic viruses for the treatment of MM and future strategies for the optimization of viral therapy for this
disease.
1.Introduction
Multiple myeloma (MM) is a clonal neoplasm of plasma
cells derived from the B-lymphocyte lineage that is part of
a spectrum of diseases ranging from monoclonal gammopa-
thy of undetermined signiﬁcance (MGUS) to plasma cell
leukemia. It is the most common primary bone cancer and
involves malignant plasma cells progressively inﬁltrating the
bonemarrow and producingamonoclonalimmunoglobulin
(Ig) (M-protein) [1]. Overt myeloma (advanced disease)
is manifested by pathophysiological consequences such as
osteolytic bone lesions, hypercalcemia, recurrent bacterial
infections, anemia, and renal failure [2]. Over 70,000
people in North America are currently aﬀected by MM
with an annual incidence of greater than 15,000. Presently,
MM accounts for 10% of hematological malignancies and
represent 1-2% of all cancer-related deaths [3]. The disease
remains incurable with current treatments with a median
survival of 3–5 years [4, 5]. MM follows a relapsing course
in the majority of patients, regardless of treatment regimen
or initial response to treatment. Accordingly, it has become
imperativetoﬁndnovel,moreeﬀectivetreatmentoptionsfor
MM.
1.1. Currently Available Therapies for Multiple Myeloma.
Disease management of MM has improved with the intro-
duction of several new agents such as bortezomib (Velcade,
a proteasome inhibitor), thalidomide, and the thalidomide
analogue lenalidomide (Revlimid, immune modulator), and
thus these drugs have now become current mainstays in
MMtreatment.Theseagentsasmonotherapies(bortezomib)
or in combination (thalidomide or lenalidomide) with dex-
amethasone have yielded improved patient outcome, yet
long-term tolerance and toxicities associated with these
drugs are limitations [6].
Stem cell rescue following high-dose chemotherapy with
autologous (ASCT) transplantation has historically become
standard therapy for the subset of good-performance
younger patients with MM. Yet minimal residual disease
and/or contaminating tumour cells within the autograft
leading to relapse is a concern with ASCT.2 Bone Marrow Research
1.2.A Historical Perspective of OncolyticViruses. The concept
of virotherapy in the treatment of cancer dates back to
the early 20th century and more recently with a report of
virally mediated tumour regression involving a patient with
cervical carcinoma that received an attenuated rabiesvaccine
[7]. Spontaneous remissions of heamatological malignancies
such as Burkitt’s lymphoma and Hodgkin’s disease have also
been observed subsequent to clinical infections with measles
virus [8, 9]. Reports as early as the 1920s indicate that viral
replication was responsible for consequent lysis of tumour
in murine models [10]. Although anecdotal, these early
observationsprovidedthefoundationtotreatcancerpatients
with oncolytic viral therapy in the late 1940’s; however,
results were disappointing likely owing in part to the rapid
viral clearance by the resultant induced immune response
[11].
Despite these setbacks over the last 15 years, there has
been a revival of interest in developing oncolytic viruses
as potential cancer therapeutics. An increasing number of
viruses have been shown to have oncolytic activity against
both solid and haematological tumours in vitro and in vivo.
The potential obstacles/limitations to a successful viable
oncolytic therapeutic platform include: large-scale GMP
viral production,toxicity,immunogenicity and optimization
of the schedule/route of administration.
Naturally occurring or engineered oncolytic viruses have
the theoretical therapeutic advantage over other cancer
therapies in that they can speciﬁcally infect, propagate, and
lyse cancer cells (including neighboring cancer cells) while
sparing normal cells. Viral speciﬁcity depends on two major
mechanisms to produce a productive viral infection and
subsequent cell lysis/death: (i) receptor-mediated uptake,
where cancer cells overexpress virus entry speciﬁc receptors,
and (ii) Utilization of aberrant cellular oncogenic signaling
pathways for virus replication. With the use of recombi-
nant DNA technology, and our increasing understanding
of microRNA functions, the capacity for creating novel
“designer viruses” appears to be limitless and therefore very
promising. Viruses genetically engineered to express suicidal
genes, immune stimulatory products within the tumor
and/or tumor-speciﬁc inﬂammatory responses, and limit
replicative potential in normal cells are attractive candidates
to be used as cancer therapeutics.
2.VirusesUsed asTherapeutic
StrategiesforMM
Of the many viruses that are currently considered possi-
ble cancer therapeutics, four RNA viruses (measles virus,
vesicular stomatitis virus, reovirus, coxsackievirus A21) and
two DNA viruses (adenovirus and vaccinia virus) have
been investigated as potential therapeutics for MM. These
have been investigated preclinically as monotherapy, as
combination therapy in conjunction with chemotherapy
and/orradiationtherapyandaspurgingagentsduringASCT.
Targeting multiple myeloma with virotherapy clinically
was ﬁrst attempted in the late 1980s, involving intravenous
treatment of a Japanese male MM patient with an attenuated
AS vaccinia strain that demonstrated signiﬁcant reductions
in his IgA monoclonal protein levels [12]. The ﬁrst formal
oncolytic viral MM clinical trial was conducted at the
Mayo clinic with an attenuated oncolytic measles virus
encoding thyroid sodium iodine symporter in order to
improve sodium iodine uptake [13]. In addition, other
naturally occurring viruses such as reovirus that is currently
undergoing phase III clinical trial testing for solid tumour
histologies are anticipated to undergo a phase I clinical trial
for MM in the near future.
2.1. Measles Virus (MV). Measles virus is the most compre-
hensively studied oncolytic virus for MM and is the ﬁrst to
undergo phase I clinical trial investigation for this disease. It
isa negative-strand RNAvirusofthegenusMorbillivirus that
causes the infectious measles syndrome. Its genome consists
of 6 genes that encode 8 proteins: the nucleocapsid (N),
phospho (P), matrix (M), fusion (F), hemagglutinin (H),
and large (L) proteins in addition to C and V accessory
proteins. The virus enters cells through the interaction of H-
glycoprotein with the CD46 receptor that is overexpressed
in cancer cells including MM [14, 15] and the signaling
lymphocyte-activation molecules (SLAM) that are found in
B- and T-lymphocytes [16]. After receptor recognition by
the H-protein, the conformational changes that take place in
the F-protein lead to viral entry and cell fusion. Cytopathic
eﬀects of MV are mediated by massive cell fusion due to
virus receptor recognition and the formation of syncytia
(large mononuclear cell aggregates) [17]. The MV-Edm
(Edmonston vaccine strain) is a replicating measles strain
that was isolated from an 11-year-old pediatric patient and
hitherto named after him. This virus has been attenuated
after serial tissue culture passage and has been administered
as a vaccine for over 50 years. Reversal of this strain to a
virulent form has never been reported, and thus it has been
exploited as cancer therapeutics based on its longstanding
safety proﬁle.
2.1.1. Preclinical Studies with MV. The success of MV-Edm
has been in part linked to the mutations of the H-
glycoprotein that leads to improved interactions with the
CD46 receptor [18], and it is of interest that over expression
of CD46 in cancer cells has been correlated with enhanced
cell death [19].
The earliest in vitro and in vivo work with MV-Edm
and MM was carried out by Peng et al. in 2001 [20]. This
study demonstrated eﬀective lysis of MM cell lines in vitro as
well as patient MM tumor utilizing a GFP-tagged MV-Edm,
with no adverse eﬀects on normal blood lymphocytes. MM
tumoursimplantedinaSCID/NODmurinexenograftmodel
also showed complete tumour regression following intratu-
moural MV treatment and signiﬁcant tumour response with
intravenous virus treatment.
A major drawback of standard viral vectors is the poor
delivery eﬃciency, especially in a clinical setting. Several
strategies have beenadopted with MV for betterdelivery and
to produce enhanced bystander eﬀects that will facilitate the
killing of tumour cells that are shielded from virus. The MV-
Edm derivatives utilizing human carcinoembryonic anti-
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(NIS; MV-NIS) have successfully been utilized to produce
signiﬁcant localbystandereﬀectsthrough cell-cellfusionand
syncytia formation [21–25].
In addition to enhancing tumour targeting strategies,
these engineered derivatives provide a means of tracking the
in vivo spread of the virus and virus gene expression/kinetics
over time. These parameters provide insight for tailoring
viral delivery doses and frequencies of repeated cycles
which could lead to a personalized approach of treatment.
While both MV-NIS and MV-CEA allow expedient real-
time monitoring of viral gene expression, MV-NIS has an
additional advantage in that it carries a membrane ion
channel (NIS)thatcanconcentrateradioisotopeswithin cells
thereby causing localization and the spread of the virus. This
unique advantage of isotope trapping by NIS facilitates the
non-invasive detectionofthespreadofthevirus byγ camera,
PET, or SPECT/CTby using radioisotope tracers such as 123I,
124I, and 99MTc [26].
The oncolytic potential of MV-NIS against MM was
investigated by Dingli et al. 2004 [22]. In vitro MM cell lines
and ex vivo MM tumour specimens showed marked sensi-
tivity, and the therapeutic eﬃcacy of MV-NIS against MM
xenografts was noteworthy as previously MV-NIS resistant
MM1 tumours showed complete regression of tumour with
combination therapy with 123I.
2.1.2. Clinical Studies with MV. The preclinical eﬃcacy and
the safety data generated for MV-NIS have translated these
ﬁndings to a phase I clinical trial for recurrent or refractory
MM that is ongoing at present [13]. This trial includes
the intravenous administration of MV-NIS with or without
cyclophosphamide. In addition to being a chemotherapeutic
drug, cyclophosphamide is an immune suppressor, and thus
prolonged viral dissemination and replication within these
immune-suppressed patients are expected as previously seen
in animal models [27]. A 2-step protocol for the phase I
clinical trial was adapted where the maximum tolerated dose
is to be evaluated in the ﬁrst step where patients will be given
intravenous injections of MV-NIS ranging from 106 to 109
T C I D - 5 0 .T h es e c o n ds t e pw i l lc o m m e n c eo n c et h eM T Di s
reached where patients in groups of 3 will be pretreated with
cyclophosphamide two days prior to MV-NIS injection. Pre
and posttherapy hematological and biochemical parameters
as well as antimeasles immunity will be determined in
the patients. In addition to measurements of MV-NIS
levels in blood, urine, and gargle samples, patients would
undergo serial imaging of virus biodistribution post-123I
administration [13]. CD46 expression of patient myeloma
cells isolated from bone marrow will be correlated with virus
infectivity in order to validate previous laboratory in vitro
studies. Interestingly, unpublished observations as reported
by Msaouel etal. [26]indicatetheuptakeof 123Iinalocalized
MM tumour of one patient as revealed by a SPECT/CT8
scanning 8 days after treatment. These encouraging results
would hopefully lead to advance phase II/III clinical trials in
the future.
2.2. Reovirus. Reovirus is a ubiquitous, nonenveloped
double-stranded RNA virus with minimal pathogenicity in
humans [28]. Although, in newborn and severely immuno-
compromised (SCID) mice, reovirus type 3 may cause
encephalitis, myocarditis and death [29–32], immunocom-
petent animals including humans have never exhibited any
of these toxicities [33]. Since reovirus is a common environ-
mental virus, the vast majority of humans have neutralizing
antibodies to this virus by the age of 8 [34]. Reovirus is
internalized into cells via the ubiquitous sialic acid receptor
[35] and/or the junction adhesion molecule (JAM) [36]. It
uses a strategy ofcell infection and lysis throughexploitation
of an already activated Ras/oncogenic signalling pathway in
tumor cells [35]. Thus, reovirus speciﬁcally targets tumor
cells for its replication and spares normal cells.
2.2.1. Preclinical Studies with Reovirus. The underlying
mechanism(s) behind the preferential cytotoxicity of re-
ovirus towards transformed cells has only recently been
described and appears to be at the level of intracellular
signalling and not at cell surface attachment [35]. When
reovirus resistant murine NIH3T3 cellsare transformed with
oncogenessuch asv-erbB2,sosand ras, reovirussusceptibility
is conferred [35, 37]. Reovirus likely exploits an activated
Ras/oncogenic signalling pathway, taking advantage of the
inhibition of the double-stranded RNA activated protein
kinase (PKR) found in these cells [35]. Recent data has
implicated the Ras/RalGEF/p38 pathway in an NIH 3T3
model system of reovirus oncolysis [38].
The oncolytic ability of reovirus against several neo-
plasms including breast, prostate, colorectal, brain, ovarian,
and hematological malignancies such as non-Hodgkin’s
lymphoma, chronic lymphocytic leukemia (CLL), and MM
has been shown by our group under in vitro, in vivo, and/or
ex vivo conditions [39–44].
As in other tumor types, activating mutations in the ras
gene family are frequent in MM [45, 46]. The incidence of
activating M-ras and K-ras mutationsappears tobe common
in MM and varies between 10 and 40% at presentation, but
may be as high as 70% at the time of relapse, indicating not
only a possible role in tumor progression but also potential
for reovirus sensitivity. Our laboratory exploited these
features of MM and investigated the potential of reovirus
as biological therapeutics against MM. Our initial studies
showed RPMI 8226 MM cell line and an ex vivo patient
tumour to be sensitive to reovirus [44]. Expanding on these
ﬁndings, we have tested 8 MM cell lines and 7 ex vivo patient
tumour samples in vitro and found 7 of 8 human MM cell
lines and 5 of 7 ex vivo tumor specimens exposed to reovirus
to be exquisitely sensitive [47, manuscript submitted]. In
addition, we have shown that the potent antitumour eﬃcacy
of reovirus is predominantly manifested through apoptotic
cell death[48]. These results indicate the potential use ofthis
virus as attractive therapeutic for MM.
Most MM patients have symptomatic disease at diag-
nosis, and autologous hematopoietic progenitor stem cell
transplantation (ASCT) is applicable for more than 50% of
patients with MM [49]. Stem cell rescue after high-dose
ablative therapy has proven to be an eﬀective and useful
treatmentmodalityforavarietyofhematologicmalignancies
including MM as well as a few solid tumours [50–56].4 Bone Marrow Research
Because of its low treatment-related mortality rate (<3%)
and the absence of the need for a suitable donor (allo-
transplantation), autologous transplantation has gained
widespread application, and globally the number of autol-
ogous blood and marrow transplants now surpasses the
number of allotransplants [55, 57, 58].
Although ASCT following high-dose myeloablative
chemotherapy is considered standard therapy for many mul-
tiple myeloma (MM) patients, relapse post-ASCT still
presents a major challenge in disease management. Gene-
marking studies indicate that occult clonogenic tumour cells
within the autograft may be a partial contributor to relapse
[59].
Since MM currently remains the second most common
indication following lymphoma for autotransplantation
[60], we explored the possibility of using reovirus as a purg-
ing agent for MM. In signiﬁcant contrast to its sensitivity
towards MM tumour, we have shown that reovirus does
not harm hematopoietic stem cells or their colony-forming
abilities in vitro or in vivo. Furthermore, RPMI 8226 cells
admixed with human apheresis product (AP) cells showed
complete purging when treated with reovirus. To examine
thepotentialuse ofthisstrategy underclinicalconditions,we
recently utilized a murine model system that recapitulated
the human course of MM and demonstrated that reovirus
purged autografts do not abrogate human hematopoietic
stem cell repopulation in vivo.F u r t h e r ,w eh a v es h o w n
that reovirus purging leads to complete eradication of
disease, prevents relapse, and leads to signiﬁcant survival
improvements in comparison to controls [47,m a n u s c r i p t
submitted].
2.2.2. Clinical Studies with Reovirus. Upwards of 16 Reovirus
(REOLYSIN) phase I/II clinical trials in several cancers have
shown moderate eﬃcacy, especially in combination with
radiotherapy and histology relevant cytotoxic chemotherapy
[61–66], and phase III trials are presently ongoing for
non-small cell lung carcinoma and head and neck cancers
[66]. Reovirus’s extensive preclinical eﬃcacy, replication
competency, and low toxicity proﬁle in humans have placed
it as attractive anticancer therapeutics for further clinical
testing for hematological malignancies. We anticipate that
the preclinical data generated for MM will lead to a clinical
trial of reovirus in MM and possibly a reovirus purging trial
in the near future.
2.3. Coxsackievirus A21 (CVA21). CVA21 is a nonenveloped,
positive-sense single-stranded virus that belongs to the
Picornaviridae family. Although it is known to cause res-
piratory tract infections and myositis in humans [67, 68],
its oncolytic potential has been proven in several cancer
cell lines including MM [69, 70]. Intracellular adhesion
molecule-1 (ICAM-1) and decay-accelerating factor are 2
receptors that are necessary for CVA21 infection and cell
lysis, and both these are reported to be upregulated in
cancer cells including MM in comparison to normal cells
[69, 71]. CVA21-mediated cell death is manifested through
interruption of various cellular processes such as disruption
of cellular protein synthesis, abrogation of transport of
cellular glycoproteins, proteolytic digestion of transcription
factors, and promotion of apoptosis [72].
2.3.1. Preclinical Studieswith CVA21. Work conductedby Au
et al. [69] showed that RPMI 8226, U266, and NCI-H929
cell lines were exquisitely sensitive to CVA21 producing 100–
1000 fold increases in viral progeny at 24h after infection
compared to controls. Normal peripheral blood cells in
contrast were resistant to virus infection. Similarly, patient
bone marrow biopsies exposing to CVA21 lead to purging
of CD138+ plasma cells up to 98.7% with minimal eﬀects
on progenitor function [69]. Since CVA 21 can cause severe
myositis in suckling [73] and immunocompromised mice
[70], Kelly et al. [70] utilized a microRNA- (miRNA-)
based approach to decrease virus pathogenicity. In this study
virus tropism was modulated with the expression of tissue-
(muscle-) speciﬁc miRNA within the engineered CVA21
thereby destabilizing viral replication in a tissue-speciﬁc
manner. SCID mice bearing subcutaneous Kas 6/1 MM
tumoursinjectedwithmiRT-CVA21showedcompletetumor
regression and sustained viremia but could not replicate in
cells containing complementary miRNAs and therefore did
notcause myositis. This study shows thatnaturallyoccurring
and diﬀerentially expressing miRNAs can be exploited to
modulate viral replication cycles, thus providing a new
paradigm of virotherapeutics.
2.3.2. Clinical Studies with CVA21. T od a t e ,n oc l i n i c a l
investigations have been initiated with CVA21 and MM.
However, a phase I clinical study is currently underway
for patients bearing melanoma, breast and prostate tumor
that express cellular receptor ICAM-1 with or without DAF
expression [74]. The preclinical data reported to date suggest
that CVA21 has the potential to purge MM during ASCT or
beusedas asystemic virotherapy agentforMM andwarrants
further investigation.
2.4. Vesicular Stomatitis Virus (VSV). Vesicular stomatitis
virus (VSV) is a small negative-strand enveloped RNA virus
that belongs to the Rhabdoviridae family. With a wide host
range, its ability to cause vesicular lesions in farm animals is
common [75]; however, the incidence of human infections is
rare [76] and usually benign [77]. Naturally occurring VSV
is highly sensitive to interferon (IFN) and exploits inherent
IFN dysregulated pathways in tumour cells for its replication
and eventual tumour destruction [78].
2.4.1. Preclinical Studies with VSV. Lichty et al. [79]h a v e
shown several leukemic cell lines and multiple myeloma
ex vivo patient specimens to be exquisitely sensitive to
VSV variants AV1, AV2 and heat resistant (HR) VSV [79].
In addition, this group also demonstrated that leukemic
cell lines could be purged successfully with these VSV
variants with minimal eﬀect on colony-forming ability of
hematopoietic stem cells suggesting potential use of these
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of the ex vivo purging eﬃcacy of these VSV variants has not
been undertaken.
Due to its small size, VSV is amenable to genetic
manipulation, and recently VSV
￿51 has been engineered
to express the human sodium iodide symporter (hNIS) for
combined imaging and radiotherapy of MM [80]. VSVΔ51-
hNIS generated by Goel et al. [80] was oncolytic to MM cell
lines, as well as primary patient tumours, and produced very
high titers in MM cells under in vitro conditions. VSVΔ51-
hNIS administered to bg/nd/xid mice bearing subcutaneous
myeloma tumors demonstrated signiﬁcant tumour regres-
sion, and high intratumoral virus replication was noted [80].
Utilizing a syngeneic 5TGM1 murine model of MM,
Goel et al. [80] further demonstrated the in vivo oncolytic
ability of VSVΔ5 1 - h N I Sw h e r es u b c u t a n e o u so ro r t h o t o p i c
tumours treated with VSVΔ51hNIS in combination of 131I
showed marked reduction of tumour and improved rates of
survival of mice.
2.4.2.Clinical StudieswithVSV. SinceMMisaradiosensitive
tumour, in vivo work conducted with VSV
￿51hNIS suggests
the potential usage of this virus in combination therapy for
clinical use in the future for MM.
2.5.Vaccinia Virus(VV). Vacciniavirusbelongstothefamily
poxviridae and is a close relative of the smallpox virus [81].
It is a double stranded DNA virus with a large genome that
is (of 190KB) amenable to genetic manipulation. Due to
its strong immunogenic nature (that results in high T-cell
responses and circulating antibodies), VV has been utilized
as a vaccine that is instrumental in eradicating smallpox
[82]. Various VV strains have further been exploited in
immunotherapy of cancer and infectious diseases and as
cancer therapeutics itself [82, 83].
2.5.1. Preclinical Studies with Vaccinia Virus (VV). The
thymidine kinase (TK) gene of VV serves as a site of DNA
insertion, and the ﬁrst logical oncolytic VV was developed
by McCart et al. [84] which is highly attenuated. In this
doublemutantVV, the TK and vaccinia growth factor (VGF)
genes have been deleted and the gene for enhanced green
ﬂuorescent protein (EGFP) has beeninserted at the TK locus
resulting in a double-deleted GFP construct (vvDD-GFP).
This attenuated virus’s tumour selectivity, safety proﬁle, and
oncolytic eﬀects have been evaluated in MM recently [85].
MM cell lines and ex vivo patient tumour exposed to vvDD-
GFP showed sensitivity, whereas minimal viral infectivity
was seen in normal peripheral blood mononuclearcells [85].
Systemic VV treatment of mice bearing My5 subcutaneous
xenografts or RPMI 82226 disseminated tumour showed
signiﬁcant reduction in tumour and improved survival over
the controls suggesting the potential use of this virus as a
clinical agent in the future.
2.5.2. Clinical Studies with Vaccinia Virus. The ﬁrst clinical
trial involving MM and VV virotherapy was a case study
conducted with a 67-year-old Japanese male patient with
IgA MM in the late 1980s [12]. Intravenous injections of
vaccinia strain AS administered to this patient resulted in
marked reductions in his IgA levels from 1,309 mg/dl in the
early stages of treatment to 432 mg/dl on the 96th day of the
regimen. No adverse eﬀects were noted.
Since then, other clinical trials of VV mutants such
as JX-594 have been conducted in patients with refractory
primaryormetastatic livercancerwithindicationsofeﬃcacy
[83]. JX-594 is a targeted, thymidine kinase(-) vaccinia
virus expressing human granulocyte-macrophage colony-
stimulating factor (hGM-CSF) and is designed to selectively
replicate in and destroy cancer cells with cell-cycle abnor-
malities and epidermal growth factor receptor- (EGFR-) Ras
aberrant signaling pathways. GM-CSF expression by JX-594
stimulates shutdown of tumour vasculature and antitumoral
immunity in addition to direct oncolysis. The encouraging
clinical results seen with JX-594 will hopefully lead to future
clinical trials in hematological malignancies including MM.
2.6. Adenovirus. Adenoviruses (Ad) are non-enveloped
double-stranded DNA viruses, and wild-type Ad may cause
mild clinical infections of the upper respiratory tract;
however, may cause signiﬁcant morbidity and mortality
in immune-compromised patients. The majority of studies
involving adenovirus as an oncolytic agent have utilized
attenuated nonreplicative adenoviral vectors that have been
engineered either to deliver a prodrug activating enzyme
such as thymidine kinase (TK)o re x p r e s sw i l d - t y p ep 5 3
selectively in tumour cells (reviewed in [86]). The tumour
cell selectivity of Ad is explained by the presence of the
coxsackievirus and Ad receptor (CAR receptor) on tumour
cells in association with the expression of αvβ5 or αvβ3
integrins requiredfor internalization of thesevirions intothe
tumour cell [87]. Modiﬁcation of the viral attachment ﬁbre
knob [88] is an additional strategy that has been utilized for
selective entry of Ad into tumour cells.
2.6.1.Preclinical StudieswithAdenovirusandMM. Teoh et al.
[89] showed that Ad vectors carrying the thymidine kinase
gene (TK) under the DF3 promoter could transduce OCI-
My5 and RPMI8226 MM cell lines eﬃciently. Treatment
of these cells in the presence of normal hematopoietic
progenitor (HPC) cells could lead to a >6 log purging of
tumour cells leaving the HPC cells unharmed. Similarly,
Ad-mediated delivery of p53 to MM cell lines or patient
tumour resulted in substantial apoptosis if the cells were
p53 mutant with low expression of bcl-2 [90]. In contrast,
HPC cells or normal lymphocytes were not permissive to
these Ad vectors [90]. Replicating Ad1337 with E1A and
E1B deletions has also been shown to cause cytotoxicity to
MM cell lines but not normal B cells [91]. More recently,
Fernandez et al. [92] examined growth inhibition of MM
cells potentiated by a conditionally replicating adenovirus
carrying a CD40 ligand transgene (AdEHCD40L). Their
work demonstrated that MM cell lines were susceptible to
AdEHCD40L-mediated apoptosis. RPMI 8226 xenografts in
a SCIDmurine model were reduced by 50% by AdEHCD40L
treatment, whereas treatment with the vector alone showed
onlya28%reductionintumour.SinceAd5serotypehasbeen6 Bone Marrow Research
Table 1: Genetic composition,advantages, and disadvantages of oncolytic viruses presently evaluated for the treatment of MM.
Measles virus VSV Reovirus CVA21 Adenovirus Vaccinia virus
Genetic composition ssRNA ssRNA dsRNA ssRNA dsDNA dsDNA
Ability to genetically
manipulate Easy Moderate Very diﬃcult Moderate Easy Easy
Titres achievable at
clinical grade >109 PFU/ml >109 PFU/ml >109 PFU/ml >1010 PFU/ml >1012 PFU/ml >109 PFU/ml
Ease of production Easy Diﬃcult Easy ? Easy Easy
Preclinical References References References References References References
in vitro [20, 22][ 79, 80][ 44, 47][ 69, 70][ 89–93][ 85]
ex vivo [20, 22][ 80][ 44, 47][ 69][ 92, 93][ 85]
purging [79][ 44, 47][ 69][ 89]
Preclinical
in vivo [20, 22, 23][ 80][ 47][ 70][ 92, 93][ 85]
Clinical studies
Multiple myeloma Phase I (13) N/A Under
discussion N/A N/A Case study (12)
Other histologies
Recurrent
glioblastoma
multiforme,
recurrent
ovarian cancer
(26)
N/A
Phase III for
solid tumours
(66)
Phase I- for
melanoma,
breast, prostate
(74)
Phase I/II for
several solid
tumours and
melanoma (106)
Phase I for
primary or
metastatic liver
cancer
Strategies for delivery of
virus forMM Intravenous Intravenous Intravenous Intravenous Intravenous Intravenous
VSV: vesicular stomatitisvirus; CVA2: coxsackie virus A21; N/A: not available.
approved for human use in solid tumours, Senac et al. [93]
investigated the potential use of Ad5 for MM. Their work
demonstrated that Ad5 could infect and kill the majority of
myeloma cell lines and ex vivo patient tumour as evidenced
byreporter geneexpression, viral DNAexpression, viraltitre,
and cell death assays. When MM patient specimens were
exposed to diﬀerent adenovirus species, many showed the
capability to kill MM tumour of patient origin and thus
suggested signiﬁcant therapeutic potential.
Although the therapeutic advantages of adenoviruses
as an oncolytic agent for MM under clinical conditions
are yet to be investigated, the eﬃcacy and safety proﬁle
of many adenoviral vectors during phase I/II clinical trials
demonstrated for solid tumours is of some concern, and
whether or not this virus could be exploited for MM therapy
in the future is unknown. Table 1 depicts a comparison of
oncolytic viruses that have been investigated for MM.
3.OptimizationofMMTreatmentwith
OncolyticVirotherapy
In the clinical setting, oncolytic viral therapy needs to be
ideally administered intravenously (IV) to MM patients due
to its hematological route of disease progression. The main
obstacles that prevent successful delivery of IV-injected virus
to tumour sites are recognition and irreversible clearance of
viral antigens by the immune system, nonspeciﬁc clearance
of virus by the liver and spleen, and minimal extravasation
of virus from the blood vessels to the targeted tumour site.
Various strategies have been developed by researchers to
overcome these barriers, and these are discussed in detail
below.
3.1. Immune Modulation. A major drawback of virotherapy
under clinical settings is that the majority of patients either
have baseline or generate neutralizing antibodies against
the therapeutic virus of interest. Overcoming this immune
responses would greatly enhance the therapeutic eﬃcacy
of virotherapy. Although malignancy-reported immunosup-
p r e s s i o ni sc o m m o ni nM Mp a t i e n t s[ 94], it is imperative to
develop strategies to overcome host immune viral responses
if virotherapy is to be optimized. To this end, cyclophos-
phamidehas beenshown tobeasuitableimmunosuppresant
in animal models as well as in early clinical trials with MV,
h e r p e sv i r u sa sw e l la sr e o v i r u s[ 27, 95–99]. Preclinical data
of MV-NIS in squirrel monkeys has shown prolonged viral
gene expression with cyclophosphamide administration to
animals [27]. Similar administration of cyclophosphamide
has shown to dampen the innate immune responses and
increase the therapeutic eﬃcacy of herpes virus with pro-
longed viral gene expression and enhance proliferation in
tumor [95]. Clinical studies with reovirus in combination
with cyclophosphamideare presentlybeing conductedinUK
for advanced malignancies of pancreatic, lung, and ovarian
cancer http://www.oncolyticsbiotech.com/clinical.html.T h e
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eﬀective immunomodulatory dose (MED) of cyclophos-
phamide to obtain successful immune modulation. The
secondary objective is the safety proﬁle and obtaining any
evidence of antitumour activity.
3.2. Cell Carrier Based Methods. Cell-based viral carriers are
another approach that has been developed to circumvent
immune clearance of therapeutic viruses. Mesenchymal
progenitor cells, monocytes, and T cells have demonstrated
the ability to shield virus from immune invasion and traﬃc
them to tumour sites leading to enhanced oncolysis [100–
102].
Ong et al. [100] evaluated T cells as carriers for systemic
measles virotherapy for MM in the presence of antiviral
antibodies. This study demonstrated that virus-infected T
cells expressing measles H/F fusogenic envelope glycopro-
teins could eﬃciently transfer MV infection by heterofusion
with MM cells in vitro. These T cells were more eﬃcient
in delivering virus to MM tumour sites than naked viruses
in mice that were passively immunized with low levels of
antimeaslesantibodiesillustrating asimilar strategythatmay
be feasible with MM patients harbouring low immunity.
Another strategy that has been experimented is that the
virus of choice could also multiply within the carrier cell,
disperse and infect adjacent tumour cells. A major advantage
of MM cells to be used for such a strategy is that they express
chemokines that are necessary to home to bone marrow
thereby facilitating nondestructive traﬃcking of virus to sites
of tumour target.
Since MM cell lines express CXCR4 and home to bone
marrow and tumour cells of similar histological origin are
reported to bind to one another [102–105], Munguia et al.
[102] exploited these features and recently utilized MM cell
lines themselves as viral delivery vehicles to tumour sites.
In this study, irradiated murine 5TGM1 MM cells were still
susceptible to VSV-GFP infection and were able to produce
progenyvirusatlevelssimilartononirradiatedcells.Utilizing
an orthotopic human myeloma (KAS/61 cell) model they
showed that VSV-GFP-infected myeloma cells administered
systemically could travel to sites of myeloma tumor growth
supporting the feasibility of this strategy for future use in the
clinic.
4.Conclusions/FutureDirections
During the past decade, the oncolytic viral platform has
expanded vastly resulting in the testing of many new
naturally occurring and engineered viruses as possible ther-
apeutics for MM. The present paper describes encouraging
investigation into oncolytic viruses for therapeutic agents in
the treatment of MM. In an era of personalized medicine,
MM represents an attractive target for viral therapy over
many solid tumours due to being an easily accessible tumour
where the dissemination of disease is prevalent in bone
marrow and blood. Therefore, the suitability of a viral
treatment as monotherapy, as combination therapy (with
chemotherapy and/or radiation therapy), or as a purging
agent could be evaluated ex vivo before systemic treatment
of patients. Althoughthe optimal strategy utilizing oncolytic
viruses forthe treatment of MMis unknown, itis anticipated
thatthe useofthose viruseswill notbe usedas monotherapy.
The combination of oncolytic viruses plus relevant cytotoxic
or targeted drug may well prove to be synergistic. Further,
one might envision that oncolytic virus treatment could be
usedpost-allo/-autotransplantoncehematopoieticrecovery
has been achieved.
Itappears from the advances made to date that the future
ofoncolyticvirotherapyliesincombinationtherapies(versus
monotherapy)forthis malignancy,andarationalefortesting
novel drugs for MM in combination with oncolytic viruses
is justiﬁed. A major obstacle that hinders virotherapy is the
host immune system that has evolved over the millennia in
to overcome infection. The many strategies that researchers
haveundertakentocircumventthisproblemsuchasimmune
modulation, shielding the virus in cell carrier, and so forth.
have provided insight into overcoming these barriers. Many
of the viruses mentioned in the aforementioned discussion
are presently under phase II/III testing for solid tumors, and
phase I clinical trials are ongoing with measles virus for MM.
It is expected that the outcomesof these studies will facilitate
to further testing of these viruses for MM in a clinical setting
and be approved as cancer therapeutics in the near future.
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